| Literature DB >> 27073493 |
Masato Okigami1, Koji Tanaka1, Yasuhiro Inoue1, Susumu Saigusa1, Yoshinaga Okugawa1, Yuji Toiyama1, Yasuhiko Mohri1, Masato Kusunoki1.
Abstract
5-fluorouracil (5FU) is often used in the treatment of colorectal cancer. 5FU improves the median overall and disease-free survival rates and reduces recurrence rates in patients who have undergone curative surgical resection. However, in the adjuvant setting, whether 5FU eradicates clinically undetectable micrometastases in target organs such as the liver, or whether 5-FU inhibits the adhesion of circulating tumor cells has not yet been established. In the present study, 5FU was administered following the inoculation of red fluorescent protein-expressing HT29 cells into green fluorescent protein (GFP)-transgenic nude mice to examine its inhibitory effect. 2-photon laser scanning microscopy was performed at selected time points for time-series imaging of liver metastasis of GFP-transgenic mice. The cell number in vessels was quantified to evaluate the response of the tumor microenvironment to chemotherapy. HT29 cells were visualized in hepatic sinusoids at the single-cell level. A total of 2 hours after the injection (early stage), time-series imaging revealed that the number of caught tumor cells gradually reduced over time. In the 5FU treatment group, no significant difference was observed in the cell number in the early stage. One week after the injection (late stage), a difference in morphology was observed. The results of the present study indicated that 5FU eradicated clinically undetectable micrometastases in liver tissues by acting as a cytotoxic agent opposed to preventing adhesion. The present study indicated that time-series intravital 2-photon laser scanning microscopic imaging of metastatic tumor xenografts may facilitate the screening and evaluation of novel chemotherapeutic agents with less interindividual variability.Entities:
Keywords: 2-photon laser-scanning microscopy; 5-fluorouracil; extravasation; liver metastasis
Year: 2016 PMID: 27073493 PMCID: PMC4812571 DOI: 10.3892/ol.2016.4258
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967